Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials (Q37223541)

19 August 2017

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials (English)

1 reference

19 August 2017

1 reference

5

Alexia Iasonos

1 reference

19 August 2017

7

Carol Aghajanian

1 reference

19 August 2017

Michelle L Harrison

1

1 reference

19 August 2017

Martin E Gore

2

1 reference

19 August 2017

David Spriggs

3

1 reference

19 August 2017

Stan Kaye

4

1 reference

19 August 2017

Martee Hensley

6

1 reference

19 August 2017

Ennapadam Venkatraman

8

1 reference

19 August 2017

Paul Sabbatini

9

1 reference

19 August 2017

language of work or name

English

0 references

publication date

5 July 2007

1 reference

19 August 2017

1 reference

19 August 2017

106

1 reference

19 August 2017

3

1 reference

19 August 2017

469-475

1 reference

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination Regimens

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694792

Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

3 September 2018

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Consolidation for ovarian cancer in remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin–paclitaxel chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2007.05.008

10.1016/J.YGYNO.2007.05.008

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

17614127

1 reference